SG11202010387QA - Starting dose of pth conjugates - Google Patents
Starting dose of pth conjugatesInfo
- Publication number
- SG11202010387QA SG11202010387QA SG11202010387QA SG11202010387QA SG11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA SG 11202010387Q A SG11202010387Q A SG 11202010387QA
- Authority
- SG
- Singapore
- Prior art keywords
- starting dose
- pth
- conjugates
- pth conjugates
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18173155 | 2018-05-18 | ||
PCT/EP2019/062773 WO2019219896A1 (en) | 2018-05-18 | 2019-05-17 | Starting dose of pth conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010387QA true SG11202010387QA (en) | 2020-11-27 |
Family
ID=62217789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010387QA SG11202010387QA (en) | 2018-05-18 | 2019-05-17 | Starting dose of pth conjugates |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210196801A1 (ko) |
EP (1) | EP3793587A1 (ko) |
JP (1) | JP2021524445A (ko) |
KR (1) | KR20210013584A (ko) |
CN (1) | CN112334152A (ko) |
AU (1) | AU2019270464A1 (ko) |
BR (1) | BR112020022306A2 (ko) |
CA (1) | CA3099620A1 (ko) |
MX (1) | MX2020012179A (ko) |
SG (1) | SG11202010387QA (ko) |
WO (1) | WO2019219896A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200276276A1 (en) * | 2016-03-01 | 2020-09-03 | Ascendis Pharma Bone Diseases A/S | PTH Prodrugs |
EP4275677A3 (en) | 2016-09-29 | 2024-01-10 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
WO2018060312A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Pth compounds with low peak-to-trough ratios |
CA3161101A1 (en) * | 2020-01-13 | 2021-07-22 | Kennett Sprogoe | Hypoparathyroidism treatment |
JP2023543265A (ja) * | 2020-09-28 | 2023-10-13 | アセンディス ファーマ ボーン ディジージズ エー/エス | 副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
AU2004273573B2 (en) | 2003-09-19 | 2010-04-22 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US8377917B2 (en) | 2004-03-23 | 2013-02-19 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
MXPA06012980A (es) * | 2004-05-10 | 2007-06-12 | Nastech Pharm Co | Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
CA2662978A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
KR101631323B1 (ko) | 2007-06-21 | 2016-06-17 | 엑스엘-프로테인 게엠베하 | 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 |
US20090016985A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
JP5588354B2 (ja) | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー/エス | 自己切断可能なリンカーを含むプロドラッグ |
WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
US20130030359A1 (en) | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
JP5977229B2 (ja) | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
ES2691642T3 (es) | 2010-05-21 | 2018-11-28 | Xl-Protein Gmbh | Polipéptidos de enrollamiento al azar de prolina/alanina biosintéticos y sus usos |
WO2012002047A1 (ja) | 2010-06-30 | 2012-01-05 | Necソフト株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
JP6092867B2 (ja) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー/エス | 担体連結しているトレプロスチニルプロドラッグ |
EP2741778A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
EP2741744A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
WO2013024049A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
WO2013160340A1 (en) | 2012-04-25 | 2013-10-31 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
EP3193941B1 (en) | 2014-08-06 | 2024-05-22 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
US20200276276A1 (en) * | 2016-03-01 | 2020-09-03 | Ascendis Pharma Bone Diseases A/S | PTH Prodrugs |
EP4275677A3 (en) * | 2016-09-29 | 2024-01-10 | Ascendis Pharma Bone Diseases A/S | Dosage regimen for a controlled-release pth compound |
MA46428A (fr) * | 2016-09-29 | 2019-08-07 | Ascendis Pharma Bone Diseases As | Schéma posologique incrémentiel dans des composés de pth à libération contrôlée |
-
2019
- 2019-05-17 AU AU2019270464A patent/AU2019270464A1/en active Pending
- 2019-05-17 MX MX2020012179A patent/MX2020012179A/es unknown
- 2019-05-17 JP JP2020564461A patent/JP2021524445A/ja active Pending
- 2019-05-17 SG SG11202010387QA patent/SG11202010387QA/en unknown
- 2019-05-17 KR KR1020207036187A patent/KR20210013584A/ko unknown
- 2019-05-17 EP EP19724825.5A patent/EP3793587A1/en active Pending
- 2019-05-17 WO PCT/EP2019/062773 patent/WO2019219896A1/en active Application Filing
- 2019-05-17 CA CA3099620A patent/CA3099620A1/en active Pending
- 2019-05-17 US US17/055,695 patent/US20210196801A1/en active Pending
- 2019-05-17 CN CN201980041822.5A patent/CN112334152A/zh active Pending
- 2019-05-17 BR BR112020022306-9A patent/BR112020022306A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CN112334152A (zh) | 2021-02-05 |
WO2019219896A1 (en) | 2019-11-21 |
EP3793587A1 (en) | 2021-03-24 |
US20210196801A1 (en) | 2021-07-01 |
MX2020012179A (es) | 2021-01-29 |
KR20210013584A (ko) | 2021-02-04 |
AU2019270464A1 (en) | 2020-11-19 |
BR112020022306A2 (pt) | 2021-02-23 |
CA3099620A1 (en) | 2019-11-21 |
JP2021524445A (ja) | 2021-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
SG11202010387QA (en) | Starting dose of pth conjugates | |
GB201804255D0 (en) | Macrophage-based therapy | |
GB201615442D0 (en) | Dose setting mechanism | |
IL282330A (en) | therapeutic compounds | |
IL284047A (en) | Combined treatment of HBV | |
GB201819853D0 (en) | Therapy | |
GB201716942D0 (en) | Therapeutic compounds | |
SG11202008718UA (en) | Combination therapy for cardiovascular diseases | |
GB201615439D0 (en) | Dose setting mechanism | |
IL276996A (en) | inhaler | |
IL269169A (en) | New dosage form | |
GB201808150D0 (en) | Therapeutic compounds | |
ZA201907286B (en) | A pharmaceutical combination for the treatment of a cancer | |
PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
EP3801713C0 (en) | INHALER | |
GB201820895D0 (en) | Therapy | |
GB2569410B (en) | Booster burner | |
GB201814038D0 (en) | Ilven therapy | |
GB201712884D0 (en) | Novel therapeutic compounds | |
GB201809828D0 (en) | Combined hormal therapy | |
GB201814652D0 (en) | Tube capsule etc | |
GB201712388D0 (en) | Therapeutic compounds | |
GB201712392D0 (en) | Therapeutic compounds | |
GB201712393D0 (en) | Therapeutic compounds |